Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

Avadel Pharmaceuticals plc

Avadel Pharmaceuticals ( ($AVDL) ) has issued an update. On December 8, 2025, the waiting period under the Hart-Scott-Rodino Antitrust Improvements...

Avadel Pharmaceuticals Acquisition Moves Forward with HSR Expiry

Wells Fargo analyst Benjamin Burnett maintained a Hold rating on Avadel Pharmaceuticals today and set a price target of $22.50. According to TipRan...

Avadel Pharmaceuticals (AVDL) Gets a Hold from Wells Fargo

Analysts fell to the sidelines weighing in on Avadel Pharmaceuticals (AVDL – Research Report) and Oncolytics Biotech (ONCY – Research Report) with ...

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)

Avadel Pharmaceuticals ( ($AVDL) ) has issued an announcement. On November 18, 2025, Avadel Pharmaceuticals and Alkermes plc amended their original...

Market Cap	$2.08B	P/E Ratio	133.50
52W High	$23.57	52W Low	$6.38
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	27.2%	52W Position	87.1%
Overall Score	53	Value Score	40
Quality Score	55	Technical Score	66

EPS Current Est	$0.16	EPS Next Est	$0.81
EPS Growth Est	+406.3%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVDL	$21.36	-0.14%	1.26M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVDL	$21.36	-0.1%	1.26M
3
4
5
6

AVDL

AVDL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Avadel Pharmaceuticals plc Data in Excel

Get Avadel Pharmaceuticals plc Data in Excel